{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:44:04Z","timestamp":1791380644676,"version":"4.3.3"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.psc.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T04:51:00Z","timestamp":1710823860000},"page":"367-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Psychedelics and Evidence-based Psychotherapy"],"prefix":"10.1016","volume":"47","author":[{"given":"Lewis","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"McSpadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamarie","family":"DeMarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Enten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Fonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psc.2024.02.006_bib1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"18","key":"10.1016\/j.psc.2024.02.006_bib2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.psc.2024.02.006_bib3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.psc.2024.02.006_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatr"},{"issue":"11","key":"10.1016\/j.psc.2024.02.006_bib5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.psc.2024.02.006_bib6","doi-asserted-by":"crossref","first-page":"866018","DOI":"10.3389\/fpsyg.2022.866018","article-title":"Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to embark, a transdiagnostic, trans-drug model","volume":"13","author":"Brennan","year":"2022","journal-title":"Front Psychol"},{"issue":"4","key":"10.1016\/j.psc.2024.02.006_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy","volume":"74","author":"Horton","year":"2021","journal-title":"Am J Psychother"},{"key":"10.1016\/j.psc.2024.02.006_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front Psychol"},{"key":"10.1016\/j.psc.2024.02.006_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.868103","article-title":"Toward Synergies of Ketamine and Psychotherapy","volume":"13","author":"Mathai","year":"2022","journal-title":"Front Psychol"},{"key":"10.1016\/j.psc.2024.02.006_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","article-title":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review","volume":"137","author":"Romeo","year":"2021","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.psc.2024.02.006_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.psc.2024.02.006_bib12","doi-asserted-by":"crossref","first-page":"788155","DOI":"10.3389\/fphar.2021.788155","article-title":"Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression","volume":"12","author":"Murphy","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.psc.2024.02.006_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcbs.2019.11.002","article-title":"Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame","volume":"15","author":"Sloshower","year":"2020","journal-title":"J\u00a0Context Behav Sci"},{"key":"10.1016\/j.psc.2024.02.006_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcbs.2019.12.004","article-title":"The use of the psychological flexibility model to support psychedelic assisted therapy","volume":"15","author":"Watts","year":"2020","journal-title":"J\u00a0Context Behav Sci"},{"key":"10.1016\/j.psc.2024.02.006_bib15","article-title":"Must Psilocybin Always \u201cAssist Psychotherapy\u201d","author":"Goodwin","year":"2023","journal-title":"Am J Psychiatr"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S0033291720005292","article-title":"The evidence for cognitive behavioural therapy in any condition, population or context: a meta-review of systematic reviews and panoramic meta-analysis","volume":"51","author":"Fordham","year":"2021","journal-title":"Psychol Med"},{"issue":"10","key":"10.1016\/j.psc.2024.02.006_bib17","doi-asserted-by":"crossref","first-page":"e0204890","DOI":"10.1371\/journal.pone.0204890","article-title":"Effectiveness of Motivational Interviewing on adult behaviour change in health and social care settings: A systematic review of reviews","volume":"13","author":"Frost","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.psc.2024.02.006_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000515756","article-title":"Effectiveness of Supportive-Expressive Group Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis","volume":"44","author":"Lai","year":"2021","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.psc.2024.02.006_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"key":"10.1016\/j.psc.2024.02.006_bib20","doi-asserted-by":"crossref","first-page":"100538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.psc.2024.02.006_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1049731513503047","article-title":"Meta-Analysis and Systematic Review Assessing the Efficacy of Dialectical Behavior Therapy (DBT)","volume":"24","author":"Panos","year":"2014","journal-title":"Res Soc Work Pract"},{"issue":"3","key":"10.1016\/j.psc.2024.02.006_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40501-020-00211-1","article-title":"Harnessing the Healing Power of Relationships in Trauma Recovery: a Systematic Review of Cognitive-Behavioral Conjoint Therapy for PTSD","volume":"7","author":"Liebman","year":"2020","journal-title":"Curr Treat Options Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2024.02.006_bib23","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib24","doi-asserted-by":"crossref","first-page":"1840123","DOI":"10.1080\/20008198.2020.1840123","article-title":"MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial","volume":"11","author":"Monson","year":"2020","journal-title":"Eur J Psychotraumatol"},{"issue":"5","key":"10.1016\/j.psc.2024.02.006_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/ADM.0000000000000338","article-title":"Mindfulness-based Relapse Prevention for Substance Use Disorders: A Systematic Review and Meta-analysis","volume":"11","author":"Grant","year":"2017","journal-title":"J\u00a0Addiction Med"},{"key":"10.1016\/j.psc.2024.02.006_bib26","doi-asserted-by":"crossref","first-page":"102115","DOI":"10.1016\/j.cpr.2021.102115","article-title":"Exposure therapy for PTSD: A meta-analysis","volume":"91","author":"McLean","year":"2022","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.psc.2024.02.006_bib27","doi-asserted-by":"crossref","first-page":"100684","DOI":"10.1016\/j.jocrd.2021.100684","article-title":"A\u00a0systematic review and meta-analysis on the effectiveness of exposure and response prevention therapy in the treatment of Obsessive-Compulsive Disorder","volume":"31","author":"Ferrando","year":"2021","journal-title":"J\u00a0Obsessive-Compuls Relat Disord."},{"issue":"3","key":"10.1016\/j.psc.2024.02.006_bib28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.15l10138","article-title":"Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial","volume":"77","author":"Rodriguez","year":"2016","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2024.02.006_bib29","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.biopsych.2020.02.563","article-title":"Repeated Sub-Anesthetic Ketamine to Enhance Prolonged Exposure Therapy in Post-Traumatic Stress Disorder: A Proof-Of-Concept Study","volume":"87","author":"Shiroma","year":"2020","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2024.02.006_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000457960","article-title":"Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression","volume":"86","author":"Wilkinson","year":"2017","journal-title":"Psychother Psychosom"},{"issue":"5","key":"10.1016\/j.psc.2024.02.006_bib31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial","volume":"90","author":"Wilkinson","year":"2021","journal-title":"Psychother Psychosom"},{"issue":"2","key":"10.1016\/j.psc.2024.02.006_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A\u00a0Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatr"},{"issue":"2","key":"10.1016\/j.psc.2024.02.006_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatr"},{"issue":"11","key":"10.1016\/j.psc.2024.02.006_bib34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A\u00a0Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am J Psychiatr"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/00952990.2020.1808982","article-title":"Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study","volume":"47","author":"Azhari","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"12","key":"10.1016\/j.psc.2024.02.006_bib36","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"issue":"15","key":"10.1016\/j.psc.2024.02.006_bib37","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.psc.2024.02.006_bib38","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psc.2024.02.006_bib39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J\u00a0Psychiatr Res"},{"issue":"7","key":"10.1016\/j.psc.2024.02.006_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"11","key":"10.1016\/j.psc.2024.02.006_bib41","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2024.02.006_bib43","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"issue":"7","key":"10.1016\/j.psc.2024.02.006_bib44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr"},{"issue":"5","key":"10.1016\/j.psc.2024.02.006_bib45","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.psc.2024.02.006_bib46","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","article-title":"Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients","volume":"323","author":"Shnayder","year":"2023","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.psc.2024.02.006_bib47","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"6","key":"10.1016\/j.psc.2024.02.006_bib48","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatr"},{"issue":"4","key":"10.1016\/j.psc.2024.02.006_bib49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"issue":"2","key":"10.1016\/j.psc.2024.02.006_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/1516-4446-2020-0980","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil","volume":"43","author":"Jardim","year":"2021","journal-title":"Braz J Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2024.02.006_bib51","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","article-title":"3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial","volume":"32","author":"Ot\u2019alora","year":"2018","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A\u00a0randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"issue":"3","key":"10.1016\/j.psc.2024.02.006_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","article-title":"MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder","volume":"40","author":"Bouso","year":"2008","journal-title":"J\u00a0Psychoact Drugs"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib54","doi-asserted-by":"crossref","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","article-title":"MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study","volume":"10","author":"Wolfson","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.psc.2024.02.006_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/0269881121991792","article-title":"First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder","volume":"35","author":"Sessa","year":"2021","journal-title":"J\u00a0Psychopharmacol Oxf Engl"},{"issue":"1","key":"10.1016\/j.psc.2024.02.006_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/02791072.2007.10399860","article-title":"Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence","volume":"39","author":"Krupitsky","year":"2007","journal-title":"J\u00a0Psychoact Drugs"},{"issue":"7","key":"10.1016\/j.psc.2024.02.006_bib57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbapap.2018.03.006","article-title":"D-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study","volume":"1866","author":"Pradhan","year":"2018","journal-title":"Biochim Biophys Acta, Proteins Proteomics"},{"issue":"12","key":"10.1016\/j.psc.2024.02.006_bib58","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1176\/appi.ajp.20220216","article-title":"A\u00a0Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial","volume":"179","author":"Price","year":"2022","journal-title":"Am J Psychiatr"},{"issue":"4","key":"10.1016\/j.psc.2024.02.006_bib59","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"issue":"4","key":"10.1016\/j.psc.2024.02.006_bib60","doi-asserted-by":"crossref","first-page":"e2834","DOI":"10.1002\/hup.2834","article-title":"Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials","volume":"37","author":"Dos Santos","year":"2022","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"10.1016\/j.psc.2024.02.006_bib61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J\u00a0Nerv Ment Dis"},{"issue":"3","key":"10.1016\/j.psc.2024.02.006_bib62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.psc.2024.02.006_bib63","article-title":"Multisite Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor JZP150 (PF-04457845) in Adults With Cannabis Use Disorder (CUD)","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psc.2024.02.006_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.873279","article-title":"Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default","volume":"13","author":"Yaden","year":"2022","journal-title":"Front Psychol"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X24000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X24000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T21:37:26Z","timestamp":1715117846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X24000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0193953X24000078"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2024.02.006","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics and Evidence-based Psychotherapy","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}